Carcinoma in Situ With Papillary Tumors
Also known as: Carcinoma in Situ Concurrent With Papillary Tumors
Drug | Drug Name | Drug Description |
---|---|---|
DB16479 | Inbakicept | An IL-15 receptor agonist used to treat BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. |
DB17381 | Nadofaragene firadenovec | A non-replicating adenoviral vector-based gene therapy used to treat high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB16479 | Inbakicept | Interleukin-2 receptor subunit beta | target |
DB16479 | Inbakicept | Cytokine receptor common subunit gamma | target |